• Facebook
  • Twitter
  • Google
ILCUK
  • ABOUT US
  • OUR PEOPLE
  • WORK WITH US
  • MEDIA CENTRE
  • CONTACT
Select Page
  • Culture and Society
    • Arts
    • Community
    • Connections
    • Crime
    • Government
    • Immigration
    • Inequalities
    • Intergenerational
    • International
    • Retirement
  • Finance and Wealth
    • Advice
    • Debt
    • Financial Planning
    • Housing Wealth
    • Investments
    • Pensions
    • Personal Finance
    • Savings
  • Health and Care
    • Care Homes
    • Carers
    • Diseases and Conditions
    • Immunisation
    • Life Expectancy
    • NHS
    • Nutrition and Hydration
    • Prevention
    • Social Care
  • Infrastructure
    • Built Environment
    • Education
    • Housing
    • Retirement Housing
    • Transport
  • Productivity
    • Consumption
    • Costs
    • Employment
    • Funding
    • GDP
    • Growth
    • Public Finance
    • Welfare
    • Work
  • What happens next

An economic analysis of flu vaccination

REPORTS

An economic analysis of flu vaccination

Jul 5, 2018 | REPORTS

This report presents findings from a new economic model on cost-benefit analyses for differing uptake and efficacy scenarios for the English flu vaccination programme.

Seasonal influenza remains a potent public health concern around the globe. Those with underlying health conditions are exposed to serious and even fatal consequences if they catch the flu. The flu continues to impose a serious burden on health services, as well as resulting in “productivity losses” due to poor health and premature mortality.

Given the rapidly ageing population of the UK and growing pressures on the National Health Service, tackling influenza is an important challenge, especially during the winter months when flu and other related health conditions are most prevalent. Vaccinations are recognised as a crucial defence against flu outbreaks, helping to protect individuals directly and by creating herd immunity.

However, all health systems face financial constraints, and understanding the costs and benefits of vaccination comes into consideration by those implementing health policy.

This report, supported by an educational grant from Seqirus presents findings from a new economic model of the costs and benefits from flu vaccination in England using recent efficacy data. More specifically, it introduces a conservative, static model which provides a partial cost-benefit analysis of vaccination under various scenarios.

The model generates a cost-benefit analysis under different plausible scenarios for vaccine efficacy, the vaccination rate and the cost of the vaccine as it applies to various risk groups. The report also produces estimates of vaccination costs per death averted to enable comparison with the wider literature.

Key findings include:

  • Vaccination averts between 180,000 and 626,000 cases of influenza per year in England
  • Flu vaccination helps avert between 5,678 and 8,800 premature deaths per year
  • The vast majority of hospital cases caused by influenza are among older adults. Over 1,800 individuals hospitalised in 2016-2017 were aged between 80 and 84 – higher than any other age group
  • The human capital costs of influenza range from £90 million to £270 million
  • The NHS flu vaccination programme costs £50,610 per death averted

Ben Franklin, Assistant Director of Research and Policy said:

”Seasonal influenza remains a potent public health concern around the globe and much of the burden falls on older people. The flu continues to impose a serious burden on health services, as well as resulting in “productivity losses” due to poor health and sick days. Policymakers should take into account the economic as well as the health costs of vaccine preventable diseases when assessing the value of vaccination. Industry must work to ensure that innovations in vaccination improve the efficacy of vaccination among older people.”

Report authors: Ben Franklin and Dean Hochlaf
DOWNLOAD
← Previous Next →

RELATED ARTICLES

Caroline Dinenage MP on Innovating for Ageing

VIDEOS

read more

Innovating for Ageing 2018/19

VIDEOS

read more

Chatty Cafe Scheme wins Innovating for Ageing competition

NEWS

read more

Recent Posts

  • Caroline Dinenage MP on Innovating for Ageing
  • Innovating for Ageing 2018/19
  • Chatty Cafe Scheme wins Innovating for Ageing competition
  • Just Group and ILC announce Innovating for Ageing finalists
  • Raising quality of life in people living with dementia – MARQUE Report launch

Archives

OUR WORK

Reports
Events
Blog
News
Videos
Presentations

LEGAL

Privacy Policy

FIND US

International Longevity Centre UK
11 Tufton Street
Westminster
London
SW1P 3QB

+44 (0)207 340 0440

Out of hours press queries
+44 (0)7531 164 886

THIS SITE

Made possible by:

Website by grenier.co.uk & irenesoler.com

The ILC-UK is a registered charity (no. 1080496) incorporated with limited liability in England and Wales (company no. 3798902).
This site uses cookies to enhance the online experience of our visitors and to better understand how our website is used. By continuing to browse the site you are agreeing to our use of cookies. Find out more.